Separation of β-amyloid binding and white matter uptake of (18)F-flutemetamol using spectral analysis.

The kinetic components of the β-amyloid ligand (18)F-flutemetamol binding in grey and white matter were investigated through spectral analysis, and a method developed for creation of parametric images separating grey and white matter uptake. Tracer uptake in grey and white matter and cerebellar cortex was analyzed through spectral analysis in six subjects, with (n=4) or without (n=2) apparent β-amyloid deposition, having undergone dynamic (18)F-flutemetamol scanning with arterial blood sampling. The spectra were divided into three components: slow, intermediate and fast basis function rates. The contribution of each of the components to total volume of distribution (VT) was assessed for different tissue types. The slow component dominated in white matter (average 90%), had a higher contribution to grey matter VT in subjects with β-amyloid deposition (average 44%) than without (average 6%) and was absent in cerebellar cortex, attributing the slow component of (18)F-flutemetamol uptake in grey matter to β-amyloid binding. Parametric images of voxel-based spectral analysis were created for VT, the slow component and images segmented based on the slow component contribution; confirming that grey matter and white matter uptake can be discriminated on voxel-level using a threshold for the contribution from the slow component to VT.

[1]  J. Anderson A rapid and accurate method to realign PET scans utilizing image edge information. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  S. Lehéricy,et al.  Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl‐11C]‐2‐(4′‐methylaminophenyl)‐ 6‐hydroxybenzothiazole , 2011, Annals of neurology.

[3]  Ranjan Duara,et al.  Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. , 2015, JAMA neurology.

[4]  M. Leon,et al.  Reduced retention of Pittsburgh compound B in white matter lesions , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[7]  Mattia Veronese,et al.  Quantification of [11C]PIB PET for Imaging Myelin in the Human Brain: A Test—Retest Reproducibility Study in High-Resolution Research Tomography , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  T. Jones,et al.  Spectral Analysis of Dynamic PET Studies , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[10]  Jerry L Prince,et al.  Measurement of Radiotracer Concentration in Brain Gray Matter Using Positron Emission Tomography: MRI-Based Correction for Partial Volume Effects , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[12]  G Lucignani,et al.  Estimation of Component and Parameter Distributions in Spectral Analysis , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  Chris Buckley,et al.  Parametric imaging and quantitative analysis of the PET amyloid ligand [18F]flutemetamol , 2015, NeuroImage.

[14]  R. Vandenberghe,et al.  Whole-Body Biodistribution and Radiation Dosimetry of 18F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging , 2009, Journal of Nuclear Medicine.

[15]  L. Thurfjell,et al.  Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease , 2009, Journal of Nuclear Medicine.

[16]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[17]  Olaf B. Paulson,et al.  MR-based automatic delineation of volumes of interest in human brain PET images using probability maps , 2005, NeuroImage.

[18]  M. Modat,et al.  The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  C. Rowe,et al.  Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias , 2009, Journal of Nuclear Medicine.

[20]  Paul Edison,et al.  Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility , 2009, NeuroImage.

[21]  F. Turkheimer,et al.  The Use of Spectral Analysis to Determine Regional Cerebral Glucose Utilization with Positron Emission Tomography and [18F]Fluorodeoxyglucose: Theory, Implementation, and Optimization Procedures , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  S. Hatashita,et al.  [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer’s disease , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.